

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
12 May 2011 (12.05.2011)

(10) International Publication Number  
WO 2011/054043 A1

- (51) International Patent Classification:  
A61B 5/024 (2006.01)
- (21) International Application Number:  
PCT/AU2010/001468
- (22) International Filing Date:  
4 November 2010 (04.11.2010)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
2009905384 4 November 2009 (04.11.2009) AU
- (71) Applicant (for all designated States except US):  
AIMEDICS PTY LTD [AU/AU]; Suite 113, National  
Innovation Centre, Australian Technology Park, Eveleigh,  
New South Wales 2015 (AU).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): SKLADNEV, Vic-  
tor [AU/AU]; 1 Russell Street, Vaucluse, New South  
Wales 2030 (AU). TARNAVSKII, Stanislav [AU/AU];  
4/43 Illawarra Street, Allawah, New South Wales 2218  
(AU). MCGREGOR, Thomas [AU/AU]; 7/8-10 Ade-  
laide Street, West Ryde, New South Wales 2114 (AU).  
GHEVONDIAN, Nejhdeh [AU/AU]; 57 Hancott Street,  
Ryde, New South Wales 2112 (AU).
- (74) Agent: FREEHILLS PATENT & TRADE MARK AT-  
TORNEYS; Level 38, MLC Centre, 19-29 Martin Place,  
Sydney, New South Wales 2000 (AU).

- (81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,  
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,  
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,  
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,  
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,  
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,  
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: ALARM SYSTEMS USING MONITORED PHYSIOLOGICAL DATA AND TREND DIFFERENCE METHODS



(57) Abstract: A method and system are described for detecting a hypoglycaemic state in a patient. The patient's heart rate is monitored (102) to provide a heart-rate signal. A time-lagged signal is determined (106) as the difference between the heart-rate signal and a time-lagged version of the heart rate-signal. The heart-rate signal is filtered with a low-pass filter (110, 120) to provide a heart-rate trend. An absolute difference between the heart-rate signal and the heart-rate trend is determined (112,122) to provide an absolute-difference signal. A second time-lagged signal is determined (116, 126) as a difference between the absolute-difference signal and a time-lagged version of the absolute-difference signal. The occurrence of a hypoglycaemic condition is inferred (130, 132) dependent on the time-lagged signal and the second time-lagged signal.

WO 2011/054043 A1

## **Alarm Systems Using Monitored Physiological Data and Trend Difference Methods**

### **Field of the invention**

The present invention relates to the design of alarm systems using physiological  
5 responses. In particular such systems can be used for the non-invasive monitoring of  
hypoglycaemia.

### **Background of the invention**

Non-invasive monitoring over extended periods using wireless links to interpretation  
systems provides a potential solution to many significant health medical issues from  
10 heart disease detection to aspects of diabetes management.

Diabetes is one of the fastest growing chronic diseases world-wide with an estimated  
current incidence of over 200 million people. Of this significant and growing population  
some 10% have type 1 insulin-dependant diabetes mellitus (T1DM) and require regular  
insulin therapy. Insulin therapy is however associated with a three-fold increased risk  
15 of hypoglycaemia (low blood glucose levels). Hypoglycaemia is the most common and  
feared complication experienced by insulin-dependent patients. Its onset is  
characterised by symptoms which include sweating, tremor, palpitations, loss of  
concentration and control. Nocturnal episodes cause particular concern due to the  
association of extended periods of hypoglycaemia with coma and neurological damage.  
20 Detection of hypoglycaemia is problematic due to sampling issues and the relatively  
wide error bands of consumer devices at low blood-glucose levels.

Current technologies used for diabetes diagnostic testing and self-monitoring are well  
established. For example, glucose meter manufacturers have modified their instruments  
to use as little as  $2\mu\text{l}$  of blood and produce results in under a minute. However, devices  
25 which require a blood sample are unsatisfactory in that the sample is painful to obtain,  
and regular monitoring is not practical, particularly overnight.

US Patent No. 7,502,644 describes an invasive technique for detecting hypoglycaemia from an analysis of the time interval between ventricular depolarization and repolarisation in conjunction with associated ECG wave shapes and heights.

5 Minimally invasive continuous glucose monitors have been developed that provide valuable blood glucose data but are limited in their ability to accurately detect the small differences between normal and hypoglycaemia glucose levels.

US Pat No. 6,882,940 describes a multi-parameter non-invasive approach that seeks to detect hypoglycaemia through the combination of IR spectroscopy and skin temperature/conductivity threshold techniques.

10 The prior hypoglycaemia detection methods either suffer from being incompatible with the need for continuous monitoring or are insufficiently specific for the detection of this potentially dangerous condition. The fear of hypoglycaemia remains the major limitation to improving diabetic control in patients treated with insulin. There is a need for a convenient and specific hypoglycaemia alarm.

15 Reference to any prior art in the specification is not, and should not be taken as, an acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in Australia or any other jurisdiction or that this prior art could reasonably be expected to be ascertained, understood and regarded as relevant by a person skilled in the art.

## 20 **Summary of the invention**

It is an object of the present invention to overcome, or at least ameliorate, one or more problems of prior art systems.

According to a first aspect of the invention there is provided a method of detecting a hypoglycaemic state in a patient, the method comprising:

25 monitoring a heart rate of the patient to provide a heart-rate signal;

determining a time-lagged time sequence as the difference between the heart-rate signal and a time-lagged version of the heart-rate signal;

inferring the occurrence of a hypoglycaemic event if the difference exceeds a first specified threshold and

5       issuing an alarm if the occurrence is inferred.

According to another aspect of the invention there is provided a method of detecting a hypoglycaemic state in a patient, the method comprising:

monitoring a heart rate of the patient to provide a heart-rate signal;

filtering the heart-rate signal with a low-pass filter to provide a heart-rate trend;

10       determining an absolute difference between the heart-rate signal and the heart-rate trend to provide an absolute-difference time sequence; and

generating a time-lagged signal as a difference between the absolute-difference time sequence and a time-lagged version of the absolute-difference time sequence.

15       According to a further aspect of the invention there is provided a method of detecting a hypoglycaemic state in a patient, the method comprising:

monitoring a heart rate of the patient to provide a heart-rate signal;

determining a time-lagged signal as the difference between the heart-rate signal and a time-lagged version of the heart rate-signal;

filtering the heart-rate signal with a low-pass filter to provide a heart-rate trend;

20       determining an absolute difference between the heart-rate signal and the heart-rate trend to provide an absolute-difference signal;

generating a second time-lagged signal as a difference between the absolute-difference signal and a time-lagged version of the absolute-difference signal; and

25       inferring the occurrence of a hypoglycaemic condition dependent on the time-lagged signal and the second time-lagged signal.

The invention also resides broadly in a system comprising:

a heart-rate monitor for monitoring a heart rate of a patient; and

a processor programmed to detect a hypoglycaemic condition of the patient dependent on trends in the monitored heart rate.

As used herein, except where the context requires otherwise, the term "comprise" and variations of the term, such as "comprising", "comprises" and "comprised", are not intended to exclude further additives, components, integers or steps.

### **Brief description of the drawings**

One or more embodiments of the present invention are described below with reference to the drawings, in which:

Figure 1A is a schematic diagram of a chest-belt transmitter that may be used in the implementation of the present invention;

Figure 1B is a schematic diagram of a receiver unit that may be used in conjunction with the transmitter of Figure 1A;

Figure 2 is a flow diagram of a method for monitoring a user's heart rate and triggering an alarm if a hypoglycaemia event is detected;

Figure 3A is an example of an overnight blood glucose measurement;

Figure 3B shows a heart-rate measurement and a derived low-frequency heart-rate trend corresponding to the glucose measurement of Figure 3A;

Figure 3C shows the glucose measurement of Figure 3A together with an alarm triggered from the trend change and threshold of Figure 3D;

Figure 3D is a corresponding graph showing trend changes calculated as a difference between a current trend value at  $t = 1$  and an earlier value at  $t = i - T_{lag}$  together with a threshold value;

Figure 4A shows a heart-rate measurement and a trend obtained from a low-pass filter;

Figure 4B shows an absolute difference between the measurement and trend of Figure 4A;

Figure 5 shows an example of a fitted line used to determine a no-alarm window based on an initial blood glucose level measurement; and

- 5 Figure 6 is a flow chart of a method of adjusting parameters of the detection method of Figure 2 based on additional variables.

#### **Detailed description of the embodiments**

10 The methods and systems described herein aim to provide solutions to the problem of accurately detecting hypoglycaemia events either as a stand-alone system or in combination with technologies that directly estimate blood glucose levels such as continuous glucose monitors.

15 The described methods and systems use physiological parameter signatures which in this case distinguish hypoglycaemia. These signatures are derived from time-sequence trend-difference features within frequency ranges and time-windows that are specific to the application, in this case the detection of hypoglycaemia events.

20 Various embodiments of the system of the present invention have common features. Research by the inventors has shown that regular monitoring of physiological parameters such as an electrocardiogram (ECG) can provide the basis of accurate detection of hypoglycaemia states through establishing whether the difference between the current time-sequence trend and a time-lagged trend in the selected parameter crosses a threshold value. The threshold-crossing time of the selected parameter may be provided to an algorithm which receives other parameter responses and additional information such as a pre-bed-time finger-prick BGL value or otherwise estimated BGL values. An alarm sequence may be activated when a summation algorithm suggests the presence or imminent onset of hypoglycaemia conditions.

25

The following describes the currently implemented mode of practicing the invention. This description is not intended to limit the general nature of the invention but is given for the purpose of describing a particular embodiment.

Figures 1A and 1B illustrate a system that may be used to implement the methods described herein. In this arrangement, a patient may wear a chest-belt unit 2 which, in use, is located around the patient's the upper thoracic region. The chest-belt unit 2 may have an adjustable elasticated strap which is adapted to engage tightly around the patient's chest using a suitable and a secure fastening system which is relatively easy to engage and disengage to enable the belt unit 2 to be put on and taken  
5  
10 off without difficulty. The strap can also be adapted to fit around a child's chest in the same manner as the adult patient. The belt unit 2 incorporates an electronic housing that encloses a wireless transmitter, analogue electronic circuitry and a microcontroller.

As shown in Figure 1A, the belt unit 2 includes active biosensors 4 that may be skin surface electrodes each adapted to monitor a different physiological parameter. The sensors 4 measure physiological parameters such as skin impedance, ECG and segments thereof, including QT-interval and ST-segment, heart rate and the mean peak  
15 frequency of the heart rate. These aspects are further discussed in detail in PCT/AU02/00218, published as WO 02/069798.

The biosensors 4 provide the signals which, after being processed, amplified, and filtered by analogue electronic circuitry, are interfaced to the microcontroller ( $\mu\text{C}$ ) unit 8. The  $\mu\text{C}$  unit 8 digitises the signals using an A/D (analogue-to-digital) converter and provides the digitised signals to a wireless transmitter 6 with an aerial 10.  
20

Associated with the belt unit 2 is a receiver unit 20 which is adapted to process signals monitored by the unit 2 for analysis and alarms. The units 2 and 20 may be encoded to recognise one another for secure communication. As shown in Figure 1B, the receiver unit 20 has an aerial 22 and wireless receiver 24. Data may be stored in data storage 28 and processed by software running on the processor 26. Data communication between the components of the receiver unit 20 is provided by bus 30. The unit 20 may have one or more output units 36 including a display for displaying  
25  
30 information to the user. The outputs 36 may also include an audible alarm.

A network communication interface 34 may also be included. This permits information about the patient's physiological condition to be transmitted elsewhere, for example via an Internet connection to a health-care provider such as an endocrinologist or cardiologist. In another example information may be sent via an SMS messaging service. Thus, for example, if the units 2, 20 are monitoring a child, a message may be sent to the child's parents if an alarm is triggered.

The unit 20 may also include a user input 32 that permits additional information to be entered into the unit 20. For example, if the patient takes a reading of blood glucose level (BGL), this may be entered into the unit 20 using a keypad. Alternatively or additionally, the input 32 may be a data link to other equipment such as a continuous BGL monitor or suitably equipped finger-prick devices.

An example of a suitable monitoring system is the HypoMon described in patent application WO 2004/098405 titled "Patient Monitor".

A method 100 for monitoring physiological data to detect a hypoglycaemia event is shown in Figure 2. A patient's heart rate is monitored (step 102), for example using the units 2, 20 described with reference to Figures 1A and 1B. In method 100, the heart rate data is analysed in three different ways (steps 104-108, 110-118 and 120-128 respectively) and the results are combined to trigger an alarm if appropriate. The steps 104-134 may be performed by software running on the processor 26 of the receiver unit 20. It will be appreciated that the method 100 may have different implementations. For example, information may be forwarded from the unit 20 to a remote server for processing. The method 100 could also be performed in a distributed fashion, where different portions of the method are carried out using different processors. The method 100, or parts of the method 100, may also be performed using other processing means such as analog circuitry, application-specific integrated circuits (ASICs) or field-programmable gate arrays (FPGAs).

#### *Time-lag trend*

In step 104 the patient's heart rate is passed through a low-pass filter to obtain a low-frequency heart-rate trend. In one arrangement the filter has a time constant of 1.6 hours. Methods of selecting parameter values for the method 100 will be discussed

below. The filters may be implemented as multi-stage RC filters or similar. The filters may also be implemented as digital filters, for example as software running on processor 8 or 26.

The method 100 is illustrated with the trends shown in Figures 3 and 4, which were derived from a T1DM sufferer. Figure 3A shows an overnight profile of the patient's blood glucose level 206. Figure 3B shows the patient's raw heart rate trend 202 over the same time period. Line 204 is a low-frequency heart-rate trend output from a low pass filter (in this case with a filtering time of around 0.5 hour). Trend 204 is delayed with respect to the raw data 202 as an inherent effect of the filter.

10 In step 106 a time-lag trend is determined as a difference between a value of the trend 204 at time  $t = i$  and a past value of the trend 204 at time  $t = (i - T_{lag})$ . In the inventors' view step 106 is a normalizing process that establishes a dynamic baseline for the process before the occurrence of hypoglycaemia. The time-lag trend monitors the change in heart rate with respect to the dynamic baseline.

15 Line 208, shown in Figure 3D, is the time-lag trend for the specific example. Here,  $T_{lag}$  is 0.5 hour. In another arrangement a lag value of 1.6 hours has been used.

In step 108 the monitoring software checks whether a specified threshold has been crossed. In the example of Figure 3D line 210 designates the relevant threshold. Point 212 shows where the time-lag trend 208 crosses the threshold 210. Figure 3C illustrates how the threshold crossing maps onto the patient's blood glucose level 206. The triggering event corresponds to a drop in the patient's BGL.

#### *Difference between heart-rate and heart-rate trend*

Steps 110-118 represent another analysis of the input heart rate. In step 110 the heart rate is filtered using a low-pass filter to provide a low-frequency trend. In one implementation the time constant of the filter is 0.3 hours. Then, in step 112, the absolute difference between the raw heart-rate data and the low-frequency trend is determined. A delayed version of the raw data may be used when determining the

absolute difference. The delay is selected to match the delay inherent in the low-pass filtering.

Steps 110 and 112 are illustrated in Figures 4A and 4B. Line 302 is raw heart-rate data and line 304 is the filtered low-frequency trend. Line 306 is the absolute difference  
5 between lines 302 and 304.

The absolute difference signal is then processed in a similar way to the method of steps 104-108. That is, steps 114, 116 and 118 correspond to steps 104, 106 and 108, although the parameters used in processing may differ.

In step 114 the absolute difference signal is passed through a low-pass filter to obtain a  
10 low-frequency difference trend. In one arrangement the filter has a time constant of 2.1 hours.

In step 116 a time-lag trend is determined as a difference between a value of the low-frequency difference trend at time  $t = i$  and a past value of the trend at time  $t = (i - T_{lag})$ . The time  $T_{lag}$  need not be the same as the lag time used in step 106. In one  
15 arrangement the  $T_{lag}$  for step 116 is 2.1 hours. Then, in step 118, the monitoring software checks whether the output signal from step 116 crosses a specified threshold. If so, an intermediate flag is triggered.

Steps 120-128 represent a third strand of processing of the heart rate signal. Steps 120-128 correspond to the steps 110-118 but use a different frequency pass-band. The  
20 processing of steps 120-128 takes into account higher-frequency information than is considered in the processing of steps 110-118.

In step 120 the heart rate is filtered using a low-pass filter to provide a low-frequency trend. In one implementation the time constant of the filter is 0.3 hours. Then, in step 122, the absolute difference between the raw heart-rate data and the low-frequency  
25 trend is determined. A delayed version of the raw data may be used when determining the absolute difference. The delay is selected to match the delay inherent in the low-pass filtering.

Steps 120 and 122 may in fact be the same as steps 110 and 112. That is, if the low-pass filter of step 110 is the same as the filter used in step 110 there is no need for separate steps 120, 122 and the output of step 112 may serve as the input to steps 114 and 124.

- 5 In step 124 the absolute difference signal is passed through a low-pass filter to obtain a second low-frequency difference trend. In one arrangement the filter has a time constant of 0.17 hours. Consequently, the difference trend output from step 124 includes higher-frequency information than the difference trend output from step 114.

10 In step 126 a time-lag trend is determined as a difference between a value of the second low-frequency difference trend at time  $t = i$  and a past value of the trend at time  $t = (i - T_{lag})$ . The time  $T_{lag}$  need not be the same as the lag time used in step 106 or 116. In one arrangement the  $T_{lag}$  for step 126 is 0.17 hours. That is, the time lag signal output from step 126 relates to higher-frequency information than is represented in the output of step 116.

- 15 Then, in step 128, the monitoring software checks whether the output signal from step 126 crosses a specified threshold. If so, an intermediate flag is triggered.

The thresholds used in steps 108, 118 and 128 may differ from one another.

20 The alarm method 100 combines the outputs of steps 108, 118 and 128. Step 130 is a logical OR operation. If step 108 detects a threshold crossing OR step 118 detects a threshold crossing, then the logical OR of step 130 triggers a further intermediate flag, which is provided to the logical AND function of step 132. The other input to the logical AND is the output of step 128. If the OR function 130 is triggered AND step 128 detects a threshold crossing within a specified time window (for example 1.2 hours), then in step 25 134 an alarm is triggered by the receiver unit 20. For example, an audible alarm may be sounded, or a message may be transmitted to a carer.

Test results obtained by the inventors suggest that method 100 provides an alarm for overnight hypoglycaemia events based on heart rate trend differences with an algorithm structure having inter-subject stability.

The structure of method 100 may be summarized as follows:

$$\alpha(\text{alarm}) = \beta[[T(a) \text{ OR } T(b)] \text{ AND } \Psi[T(c)]] \text{ AND } T(w)$$

Where: T (a ) is the response time of the time-lagged difference of the low pass filter components of heart rate (low pass filter time constant 1.6 hours and lag 1.6 hours);

- 5 T (b) is the response time of the absolute difference between heart rate and heart rate trend with a 0.3 hour time constant which is further converted to a trend difference as in T (a) where the filter time constant is 2.1 hours and the lag is 2.1 hours;

T (c) varies from T (b) in that the final low-pass filter has a time constant of 0.17 hours and a lag of 0.17 hours. Additionally the time window for the associated AND  
10 function is 1.2 hours.

T (w) is a time window derived from initial conditions such as pre-bed time finger-prick BGL.

#### *Time window*

The time window T(w) is based on the observation that patients having higher blood  
15 glucose levels at the beginning of the night tend to experience hypoglycaemia later in the night than patients with relatively low initial BGL. This is illustrated in Figure 5, which shows lapsed time to the onset of hypoglycaemia versus the patients' initial BGL. Line 402 is an example of the no-alarm time window vs the initial BGL. This observation has been used to reduce the number of false alarms by disregarding alarms that are  
20 triggered in the area below line 402. To implement this window T(w), a measurement of the patient's BGL is made at the beginning of the night, for example using a finger-prick measurement. The measurement may be keyed into unit 20 using the user input 32. The monitoring software running on unit 20 takes the BGL measurement into account and disregards alarms triggered in step 134 in the initial time window.

25 *Selecting parameter values*

- The method 100 includes several parameters, including time-constants for the low pass filters, lag times for calculating the lagged signals and the values of the thresholds used in steps 108, 118 and 128. These parameters may be set by accumulating patient data including information about the onset of hypoglycaemia, and dividing the data into training data sets and test data sets. The parameter values may be determined by training algorithms that optimize the values based on the training sets. The optimized parameter values may be tested on the test data sets. Such procedures may serve to increase the detection accuracy of the method and to reduce the number of false alarms.
- 10 One method for identifying stable signatures within the complex system nature of T1DM sufferer's response to hypoglycaemia was as follows. Selected non-invasive physiological parameters along with regular venous BGL readings on gold standard (YSI) devices were monitored on 130 T1DM volunteers over a range of day/night hypoglycaemic clamp and natural conditions. Analysis of this data was guided by the hypothesis that hypoglycaemia events stimulate physiological responses which show frequency, time-lag and time-window features that have inter-subject stability. Stability evaluations on potential features were then carried out in an iterative manner by segregating the data into training and evaluation data sets. The stability of the discovered signatures was then confirmed in a blinded prospective overnight trial on 52 previously unseen T1DM sufferers.

#### *Using dynamic parameter settings*

The alarm thresholds and parameters such as decision integration times used in the described methods can be fixed or dynamic depending on the nature of the additional information available. For example, direct estimates of blood glucose levels (BGL) and trends from a continuous glucose monitor may be integrated into the alarm system in the form of a logic tree of the following general form:

- a) At high BGL estimates, ignore all alarms over a specified time window;
- b) At near-normal BGL estimates, raise the threshold of alarm features;

c) At low BGL estimates or in the event of significant trends to low BGLs, lower the alarm thresholds for selected features; and

d) At very low BGL estimates activate the alarm.

In this manner allowances may be made for variations in estimation accuracy over BGL  
5 ranges.

Alternatively, instead of adjusting the thresholds, scaling factors may be used to take additional information into account. For example, with reference to Figure 2, a scaling factor may be applied to one or more of the trends before checking whether the trends have crossed the specified threshold (e.g. in steps 108, 118 and 128). Thus, a scaling  
10 factor may be used as a multiplier for the time-lag difference obtained in step 106, and/or the time lag difference determined in step 116 and/or the time-lag difference obtained in step 126.

For example, direct estimates of blood glucose levels (BGL) and trends from a continuous glucose monitor may be integrated into the alarm system in the form of a  
15 logic tree of the following general form:

a) At high BGL estimates, ignore all alarms over a specified time window;

b) At near-normal BGL estimates, reduce one or more of the scaling factors to reduce the probability of the scaled trend exceeding the specified threshold;

c) At low BGL estimates or in the event of significant trends to low BGLs, increase one  
20 or more of the scaling factors to increase the probability of the scaled trend exceeding a specified threshold; and

d) At very low BGL estimates activate the alarm.

In this manner allowances may be made for variations in estimation accuracy over BGL ranges. The scaling coefficients may be varied dependent on the BGL value at the

beginning of the night or on the history of BGL from the beginning of the night through to the latest reading.

This is further illustrated in method 500 (see Figure 6). In step 502, additional variables such as BGL are monitored, in addition to the heart rate monitoring of step 102. Then, in  
5 step 504, one or more parameters of the alarm method 202 are adjusted, for example as described in the foregoing paragraph. These adjustments may be performed by software running on the receiver unit 20. Other arrangements may be used. For example, the adjustments may be determined by software running on a remote server and transferred to the relevant data registers 28 of the receiver unit 20.

10 In step 506 the alarm method 100 runs. If the method triggers an alarm (the YES option of step 506), then in step 508 the monitoring software checks whether the alarm should be ignored because it has been triggered within a specified time window. If appropriate, the alarm is issued in step 510, otherwise process flow returns to step 506 to continue monitoring the patient.

15 It will be evident to those experienced in device algorithm development that some details of the methods described above are illustrative of structure rather than form as specific device features will substantially influence the optimum solutions.

The foregoing describes only some embodiments of the present invention, the embodiments being illustrative and not restrictive. The intended application of the alarm  
20 system will determine the structure of the basic alarm algorithm.

Although this specification concentrates on a system and method for the detection of hypoglycaemia, it should be understood that the invention has wider application.

It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more individual features mentioned or  
25 evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.

In the context of this specification, the word "comprising" or its grammatical variants is equivalent to the term "including" and should not be taken as excluding the presence of other elements or features.

**Claims:**

1. A method of detecting a hypoglycaemic state in a patient, the method comprising:  
monitoring a heart rate of the patient to provide a heart-rate signal;  
determining a time-lagged time sequence as the difference between the heart-  
5 rate signal and a time-lagged version of the heart-rate signal;  
inferring the occurrence of a hypoglycaemic event if the difference exceeds a first  
specified threshold and  
issuing an alarm if the occurrence is inferred.
2. The method of claim 1 comprising filtering the heart-rate signal with a low-pass  
10 filter to provide a heart-rate trend, wherein the time-lagged time sequence is determined  
as the difference between the heart rate trend and a time-lagged version of the heart-  
rate trend.
3. The method of claim 1 or 2 comprising varying the first specified threshold  
dependent on one or more measured patient parameters.
- 15 4. The method of claim 3 wherein the patient parameter comprises a measured  
blood glucose level.
5. The method of claim 4 wherein, if the measured blood glucose level is high, the  
first threshold is adjusted to reduce the likelihood of inferring the occurrence of a  
hypoglycaemic event.
- 20 6. The method of claim 4 wherein, if the measured blood glucose level is near  
normal values or at low levels, the first threshold is adjusted to increase the likelihood of  
inferring the occurrence of a hypoglycaemic event.
7. The method of any one of the preceding claims wherein the method of detecting  
a hypoglycaemic state is commenced at a start time and the method comprises:  
25 determining a no-alarm window period dependent on a blood glucose value of  
the patient associated with the start time, wherein no alarm is issued if a hypoglycaemic  
event is inferred between the start time and an end time of the no-alarm window period.

8. The method of claim 7 wherein the duration of the no-alarm window is increased for higher levels of blood glucose associated with the start time.
9. A method of detecting a hypoglycaemic state in a patient, the method comprising:  
monitoring a heart rate of the patient to provide a heart-rate signal;  
5 filtering the heart-rate signal with a low-pass filter to provide a heart-rate trend;  
determining an absolute difference between the heart-rate signal and the heart-rate trend to provide an absolute-difference time sequence; and  
generating a time-lagged signal as a difference between the absolute-difference time sequence and a time-lagged version of the absolute-difference time sequence.
10. The method of claim 9 comprising inferring the occurrence of a hypoglycaemic condition if the time-lagged signal exceeds a specified threshold.
11. A method of detecting a hypoglycaemic state in a patient, the method comprising:  
monitoring a heart rate of the patient to provide a heart-rate signal;  
determining a time-lagged signal as the difference between the heart-rate signal  
15 and a time-lagged version of the heart rate-signal;  
filtering the heart-rate signal with a low-pass filter to provide a heart-rate trend;  
determining an absolute difference between the heart-rate signal and the heart-rate trend to provide an absolute-difference signal;  
generating a second time-lagged signal as a difference between the absolute-  
20 difference signal and a time-lagged version of the absolute-difference signal; and  
inferring the occurrence of a hypoglycaemic condition dependent on the time-lagged signal and the second time-lagged signal.
12. The method of claim 11 wherein the occurrence of the hypoglycaemic condition is inferred if the time-lagged signal crosses a first specified threshold and the second  
25 time-lagged signal crosses a second specified threshold.
13. The method of claim 12 comprising varying the first specified threshold and/or the second specified threshold dependent on one or more measured patient parameters.

14. The method of claim 12 comprising multiplying the time-lagged signal and/or the second time-lagged signal by a scaling factor dependent on one or more measured patient parameters.

15. The method of claim 13 or 14 wherein the patient parameter comprises a  
5 measured blood glucose level.

16. The method of claim 15 wherein, if the measured blood glucose level is high, the first threshold and/or the second threshold are adjusted to reduce the likelihood of inferring the occurrence of a hypoglycaemic event.

17. The method of claim 15 wherein, if the measured blood glucose level is near  
10 normal values or at low levels, the thresholds are adjusted to increase the likelihood of inferring the occurrence of a hypoglycaemic event.

18. The method of any one of claims 11 to 17 wherein the method of detecting a hypoglycaemic state is commenced at a start time and the method comprises:

15 determining a no-alarm window period dependent on a blood glucose value of the patient associated with the start time, wherein no alarm is issued if a hypoglycaemic event is inferred between the start time and an end time of the no-alarm window period.

19. A system for detecting a hypoglycaemic state in a patient, comprising:

a heart-rate monitor for monitoring a heart rate of the patient; and

20 a processor in data communication with the heart-rate monitor, programmed to detect a hypoglycaemic condition of the patient using the methods of any one of claims 1 to 18.

20. A computer program product comprising machine-readable program code recorded on a machine readable recording medium, for controlling the operation of a data processing apparatus on which the program code executes to perform a method of  
25 detecting a hypoglycaemic condition of the patient using the methods of any one of claims 1 to 18.

21. A computer program comprising machine-readable program code for controlling the operation of a data processing apparatus on which the program code executes to perform a method of detecting a hypoglycaemic condition of the patient using the  
30 methods of any one of claims 1 to 18.




Fig 1A




Fig 1B




Figure 2





Fig 3C




Fig 3D




Fig 4A




Fig 4B





Fig 5



7/7




Fig 6

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2010/001468

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl.		
<b>A61B 5/024</b> (2006.01)		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
WPI, EPODOC: A61B5/IC/EC/LOW & Keywords (diabetic, hypoglycemia, monitor, detect, record, heart rate, time lag, phase difference, differential, threshold) and like terms		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2007/0118054 A1 (PINHAS et al.) 24 May 2007 Abstract; Para [0322] – [0325], [0392]; FIG. 2, 5 – 7	1 – 3 and 19 – 21
X	US 2004/0077962 A1 (KROLL) 22 April 2004 Para [0010] – [0012], [0070], [0072] – [0076]; FIG. 2	1 – 6 and 19 – 21
X	US 2006/0167365 A1 (BHARMI) 27 July 2006 Abstract; Para [0097] – [0099]; FIG. 2	1 – 3 and 19 – 21
A	EP 1785088 A1 (CONGENER WELLNESS CORP.) 16 May 2007 Whole Document	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 20 December 2010		Date of mailing of the international search report 24 DEC 2010
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. +61 2 6283 7999		Authorized officer VIJAY SINGH AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No : +61 2 6283 2665

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2010/001468

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2005027183 A1 (SASTRE) 03 February 2005 Whole Document	
A	WO 2002/069798 A1 (UNIVERSITY OF TECHNOLOGY, SYDNEY) 12 September 2002 Whole document	
A	US 6390986 B1 (CURCIE et al.) 21 May 2002 Whole document	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU2010/001468

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
US	20071.18054	CA	2668602	EP	1955233	WO	2007052108
US	2004077962	EP	1419731	US	7016720	US	2004078065
		US	7029443	US	2006100494	US	7680529
US	2006167365	EP	1850909	US	2006167518	US	7272436
		US	2006167519	US	7297114	US	2006167517
		US	7502644	US	7524287	US	7756572
		US	2009177103	US	2009177104	US	2009177105
		WO	2006081336				
EP	1785088	CN	101321490	US	2008294021	WO	2007054399
US	2005027183	NONE					
WO	02069798	CA	2439276	EP	1370176	NZ	527818
		US	2004167418	US	7450986		
US	6390986	NONE					
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.							
END OF ANNEX							

专利名称(译)	报警系统使用监测的生理数据和趋势差异方法		
公开(公告)号	<a href="#">EP2496134A1</a>	公开(公告)日	2012-09-12
申请号	EP2010827716	申请日	2010-11-04
[标]申请(专利权)人(译)	AIMEDICS		
申请(专利权)人(译)	AIMEDICS PTY LTD		
当前申请(专利权)人(译)	AIMEDICS PTY LTD		
[标]发明人	SKLADNEV VICTOR TARNAVSKII STANISLAV MCGREGOR THOMAS GHEVONDIAN NEJHDEH		
发明人	SKLADNEV, VICTOR TARNAVSKII, STANISLAV MCGREGOR, THOMAS GHEVONDIAN, NEJHDEH		
IPC分类号	A61B5/024 A61B5/00		
CPC分类号	A61B5/0006 A61B5/024 A61B5/14532 A61B5/7275 G06F19/3418 G16H40/67		
优先权	2009905384 2009-11-04 AU		
其他公开文献	EP2496134A4		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

描述了一种用于检测患者的低血糖状态的方法和系统。监测患者的心率 ( 102 ) 以提供心率信号。将时间滞后信号确定 ( 106 ) 为心率信号与心率信号的时间滞后版本之间的差异。用低通滤波器 ( 110,120 ) 对心率信号进行滤波, 以提供心率趋势。确定心率信号和心率趋势之间的绝对差值 ( 112,122 ) 以提供绝对差信号。确定第二时滞信号 ( 116,126 ) 作为绝对差信号和绝对差信号的时滞版本之间的差。根据时滞信号和第二时滞信号推断出低血糖状况的发生 ( 130,132 )。